Results 61 to 70 of about 1,043 (146)

Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir [PDF]

Reviews in Medical Virology, 2008
AbstractMutations in the human CMV UL97 kinase gene are a major mechanism of viral resistance to two anti‐CMV drugs, ganciclovir (GCV) and maribavir (MBV). GCV, the most widely used and established therapy for CMV, is a substrate for the UL97 kinase.
openaire   +2 more sources

Refractory/Resistant Cytomegalovirus Infection in Transplant Recipients: An Update

Viruses
Despite the significant progress made, CMV infection is one of the most frequent infectious complications in transplant recipients. CMV infections that become refractory or resistant (R/R) to the available antiviral drugs constitute a clinical challenge ...
Léna Royston, Genovefa A. Papanicolaou, Dionysios Neofytos   +2 more
doaj   +1 more source

The effective multiplicity of infection for HCMV depends on the activity of the cellular 20S proteasome

Journal of Virology
Human cytomegalovirus (HCMV) is a betaherpesvirus capable of infecting numerous cell types and persisting throughout an infected individual’s life. Disease usually occurs in individuals with compromised or underdeveloped immune systems.
Katie M. Cataldo, Kathryn L. Roche, Christopher E. Monti, Ranjan K. Dash, Eain A. Murphy, Scott S. Terhune   +5 more
doaj   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Decoding the Landscape of Cytomegalovirus Research in Liver Transplantation: An In-Depth Analysis

High Yield Medical Reviews
Introduction: Cytomegalovirus (CMV), a prevalent viral infection post-liver transplantation, significantly influences transplant outcomes. This bibliometric analysis explores the evolving landscape of CMV-related research in liver transplantation ...
Laurie Hung, Haneen Al-Abdallat, Aasem Rawshdeh, Esra’a Rasmi Al-Zghoul, Amani Al-Rawashdeh, Mohammad Alzoubi, Badi Rawashdeh   +6 more
doaj   +1 more source

SP05 | MARIBAVIR AS ANTI-CYTOMEGALOVIRUS TREATMENT IN REFRACTORY OR RESISTANT DISEASES IN A NON-TRANSPLANT SETTING

Haematologica
Introduction: CMV infection can be life-threatening in immunocompromised patients. In the setting of allo-HSCT, different treatment strategies exist for refractory or resistant CMV disease.
U. Pizzano, G. De Cicco, D. Schiavo, E. Scarpa, M. Stanzani.   +4 more
doaj  

Proteomic Interaction Patterns between Human Cyclins, the Cyclin-Dependent Kinase Ortholog pUL97 and Additional Cytomegalovirus Proteins

Viruses, 2016
The human cytomegalovirus (HCMV)-encoded cyclin-dependent kinase (CDK) ortholog pUL97 associates with human cyclin B1 and other types of cyclins. Here, the question was addressed whether cyclin interaction of pUL97 and additional viral proteins is ...
Mirjam Steingruber, Alexandra Kraut, Eileen Socher, Heinrich Sticht, Anna Reichel, Thomas Stamminger, Bushra Amin, Yohann Couté, Corina Hutterer, Manfred Marschall   +9 more
doaj   +1 more source

Degree-based topological indices and QSPR analysis of Cytomegalovirus drugs

International Journal of Mathematics for Industry
This study examines several drugs employed in treating Cytomegalovirus (CMV) infections, including Cidofovir, Foscarnet, Ganciclovir, Maribavir, and Valganciclovir.
H. M. Nagesh
doaj   +1 more source

Antiviral Agents for Preventing Cytomegalovirus Disease in Recipients of Hematopoietic Cell Transplantation

Viruses
This systematic review discusses the use of prophylaxis to prevent cytomegalovirus (CMV) infection in recipients who have undergone hematopoietic cell transplantation. It highlights the need for new approaches to control and prevent CMV infection.
Tang-Her Jaing, Yi-Lun Wang, Chia-Chi Chiu   +2 more
doaj   +1 more source

Use of Specific T Lymphocytes in Treating Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients: A Systematic Review

Pharmaceutics
Cytomegalovirus (CMV) poses a significant threat to post-hematopoietic cell transplantation (HCT). Control strategies include letermovir prophylaxis or ganciclovir pre-emptive therapy (PET).
Tayná F. G. S. Bandeira, Luciana C. Marti, Edna T. Rother, Lucas Reis Correia, Clarisse M. Machado   +4 more
doaj   +1 more source